# Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma

> **NCT07569068** · PHASE2 · RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 88 (estimated)

## Conditions studied

- Gastric or Esophagogastric Junction Adenocarcinoma

## Interventions

- **DRUG:** Tislelizumab, LM-302 and S-1
- **DRUG:** Tislelizumab combined with oxaliplatin and S-1

## Key facts

- **NCT ID:** NCT07569068
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-21
- **Primary completion:** 2028-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07569068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07569068, "Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07569068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*